Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. McCartney · SciRah

Researcher profile · Semantic Scholar

A. McCartney

Share profile

A. McCartney — researcher profile on SciRah

h-index: 18
Works: 60
Citations: 1,279

Most-cited papers

Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).
L. Biganzoli, N. Battisti, H. Wildiers, A. McCartney +14 more
2021The Lancet Oncology240 citations Open access
Semantic Scholar
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
A. McCartney, I. Migliaccio, M. Bonechi, C. Biagioni +8 more
2019Frontiers in Oncology161 citations Open access
Semantic Scholar
Metabolomics in breast cancer: A decade in review.
A. McCartney, A. Vignoli, L. Biganzoli, R. Love +3 more
2018Cancer Treatment Reviews101 citations
Semantic Scholar
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
V. Ghini, L. Laera, B. Fantechi, F. del Monte +5 more
2020Cancers98 citations Open access
Semantic Scholar
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
L. Malorni, G. Curigliano, A. Minisini, S. Cinieri +18 more
2018Annals of Oncology86 citations Open access
Semantic Scholar
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
I. De Santo, A. McCartney, I. Migliaccio, A. Di Leo +1 more
2019Cancers75 citations Open access
Semantic Scholar
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
A. McCartney, M. Bonechi, F. De Luca, C. Biagioni +13 more
2020Clinical Cancer Research50 citations Open access
Semantic Scholar
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
I. Migliaccio, M. Bonechi, A. McCartney, C. Guarducci +4 more
2020Cancer Treatment Reviews44 citations
Semantic Scholar
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
A. McCartney, C. Biagioni, G. Schiavon, M. Bergqvist +15 more
2019European Journal of Cancer44 citations
Semantic Scholar
Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
A. Vignoli, E. Risi, A. McCartney, I. Migliaccio +5 more
2021International Journal of Molecular Sciences36 citations Open access
Semantic Scholar
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
F. Galardi, F. De Luca, C. Biagioni, I. Migliaccio +15 more
2021Breast Cancer Research33 citations Open access
Semantic Scholar
COVID‐19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study
M. Nguyen, N. Bain, L. Grech, T. Choi +9 more
2022Asia-Pacific Journal of Clinical Oncology26 citations Open access
Semantic Scholar
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
L. Malorni, S. Tyekucheva, F. Hilbers, M. Ignatiadis +29 more
2022European Journal of Cancer24 citations Open access
Semantic Scholar
A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting
S. Di Donato, A. Vignoli, C. Biagioni, L. Malorni +16 more
2021Cancers24 citations Open access
Semantic Scholar
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients
E. Risi, A. Grilli, I. Migliaccio, C. Biagioni +9 more
2018Breast Cancer Research and Treatment21 citations Open access
Semantic Scholar
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
S. Hurvitz, Haeseong Park, S. Frentzas, Catherine M. Shannon +16 more
2021Journal of Clinical Oncology20 citations
Semantic Scholar
The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.
L. Rossi, A. McCartney, I. De Santo, E. Risi +4 more
2019Cancer Treatment Reviews20 citations
Semantic Scholar
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
L. Rossi, C. Biagioni, A. McCartney, I. Migliaccio +16 more
2019Breast Cancer Research20 citations Open access
Semantic Scholar
The role of abemaciclib in treatment of advanced breast cancer
A. McCartney, E. Moretti, G. Sanna, M. Pestrin +4 more
2018Therapeutic Advances in Medical Oncology18 citations Open access
Semantic Scholar
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care.
F. Cardoso, A. McCartney, A. Ponti, L. Marotti +12 more
2023European Journal of Cancer17 citations Open access
Semantic Scholar
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
L. Rossi, A. McCartney, E. Risi, I. De Santo +4 more
2019Clinical Breast Cancer15 citations
Semantic Scholar
Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification
A. McCartney, A. Vignoli, L. Tenori, M. Fornier +5 more
2019npj Breast Cancer14 citations Open access
Semantic Scholar
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
L. Biganzoli, S. Cinieri, R. Berardi, R. Pedersini +22 more
2020Breast Cancer Research12 citations Open access
Semantic Scholar
The Conundrum of the Association of Chemotherapy With Survival Outcomes Among Elderly Patients With Curable Luminal Breast Cancer.
N. M. L. Battisti, A. McCartney, L. Biganzoli
2020JAMA Oncology10 citations
Semantic Scholar
Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature
L. Rossi, C. Biagioni, A. McCartney, E. Moretti +6 more
2018Anticancer Research8 citations Open access
Semantic Scholar
Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance.
A. McCartney, L. Malorni
2020Biomarkers in Medicine7 citations
Semantic Scholar
Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
A. McCartney, L. Malorni
2020British Journal of Cancer6 citations Open access
Semantic Scholar
A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.
G. Sanna, M. Pestrin, E. Moretti, C. Biagioni +5 more
2020Clinical Breast Cancer6 citations
Semantic Scholar
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
E. Risi, C. Biagioni, M. Benelli, I. Migliaccio +13 more
2019Therapeutic Advances in Medical Oncology6 citations Open access
Semantic Scholar
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
L. Rossi, A. McCartney, E. Risi, L. Malorni +2 more
2018Therapeutic Advances in Medical Oncology6 citations Open access
Semantic Scholar
Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
Janice M. Lu, K. Kalinsky, D. Tripathy, G. Sledge +16 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial
L. Malorni, S. Tyekucheva, F. Hilbers, M. Ignatiadis +21 more
2021Poster Session Abstracts5 citations
Semantic Scholar
De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.
A. McCartney, A. Vignoli, C. Hart, L. Tenori +3 more
2017Breast4 citations
Semantic Scholar
273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
S. Hurvitz, K. Kalinsky, D. Tripathy, G. Sledge +15 more
2022Annals of Oncology3 citations Open access
Semantic Scholar
Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines
M. Bonechi, I. Migliaccio, M. Benelli, Dario Romagnoli +16 more
2019Poster Session Abstracts3 citations
Semantic Scholar
250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
J. Lu, G. Budd, S. Frentzas, H. Park +16 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?
L. Biganzoli, A. McCartney
2020Chinese Clinical Oncology2 citations Open access
Semantic Scholar
A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)
S. Di Donato, A. Vignoli, E. Mori, L. Tenori +10 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults.
L. Biganzoli, A. McCartney, N. Battisti
2019JAMA Oncology2 citations
Semantic Scholar
Abstract P5-02-27: Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial
A. McCartney, C. Biagioni, Bing-Shu E. Chen, L. Shepherd +12 more
2023Cancer Research1 citations
Semantic Scholar
Abstract ES8-1: Adjuvant endocrine therapy in 2020: It's complicated
A. McCartney, A. Di Leo
20201 citations
Semantic Scholar
Estimating the magnitude of clinical benefit of chemotherapy in patients with early ER-positive, HER2-negative breast cancer
A. McCartney, A. Di Leo
2019Breast1 citations
Semantic Scholar
Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial
L. Malorni, C. Biagioni, F. De Luca, M. Bonechi +17 more
2019Molecular and Cellular Biology / Genetics1 citations
Semantic Scholar
Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer.
A. McCartney, M. Benelli, A. Di Leo
2019Breast1 citations
Semantic Scholar
Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution
G. Barchiesi, A. McCartney, C. Biagioni, O. Siclari +4 more
2019The Breast Journal1 citations Open access
Semantic Scholar
Adjuvant Endocrine Therapy
A. McCartney, G. Sanna, L. Biganzoli
2019Management of Breast Cancer in Older Women1 citations
Semantic Scholar
Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.
L. Malorni, C. Biagioni, A. McCartney, G. Schiavon +13 more
20181 citations
Semantic Scholar
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
N. Harbeck, E. Ciruelos, Guy Jerusalem, V. Müller +87 more
2024Nature Medicine0 citations Open access
Semantic Scholar
Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
Janice M. Lu, K. Kalinsky, D. Tripathy, G. Sledge +22 more
2022Cancer Research0 citations
Semantic Scholar
Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers.
M. Nguyen, N. Bain, L. Grech, N. Hamad +12 more
2022Journal of Clinical Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Biganzoli×32
Invite
L. Biganzoli — researcher profile on SciRah
A. Di Leo×27
Invite
A. Di Leo — researcher profile on SciRah
L. Malorni×26
Invite
L. Malorni — researcher profile on SciRah
I. Migliaccio×18
Invite
I. Migliaccio — researcher profile on SciRah

×18

Invite

E. Risi — researcher profile on SciRah

C. Biagioni×17

Invite

C. Biagioni — researcher profile on SciRah

Invite

M. Benelli — researcher profile on SciRah

Invite

E. Moretti — researcher profile on SciRah

Invite

M. Bonechi — researcher profile on SciRah

Invite

L. Rossi — researcher profile on SciRah

Invite

F. Galardi — researcher profile on SciRah

G. Curigliano×8

Invite

G. Curigliano — researcher profile on SciRah